ChartMill assigns a Buy % Consensus number of 82% to IRD. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-25 | Piper Sandler | Initiate | Overweight |
| 2025-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-29 | Wedbush | Initiate | Outperform |
| 2025-10-16 | Chardan Capital | Initiate | Buy |
| 2025-06-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-17 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2025-04-11 | Craig-Hallum | Initiate | Buy |
| 2025-04-01 | Jones Trading | Maintains | Buy -> Buy |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
11 analysts have analysed IRD and the average price target is 7.87 USD. This implies a price increase of 252.85% is expected in the next year compared to the current price of 2.23.
The consensus rating for OPUS GENETICS INC (IRD) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering OPUS GENETICS INC (IRD) is 11.